BioPharmSignal logoBioPharmSignal

Biotech News

Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Arcutis Biotherapeutics (ARQT)Arcutis BiotherapeuticsCompany update

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals with independent, board-certified dermatologists through a streamlined digital experience for

Related news

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

ARQTArcutis Biotherapeutics2026-04-27 12:00 EST

Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months

View all latest news

Arcutis Biotherapeutics

Medical Dermatology Arcutis Biotherapeutics develops and commercializes targeted therapies for immune-mediated skin diseases, emphasizing convenient topical formulations against validated biology. ZORYVE Franchise ZORYVE is a once-daily topical roflumilast product available in cream and foam formulations across plaque psoriasis, atopic...

Recent company news

ARQTArcutis Biotherapeutics2026-08-07 20:00 EST

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQTArcutis Biotherapeutics2026-08-05 20:00 EST

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

ARQTArcutis Biotherapeutics2026-07-16 13:00 EST

Arcutis Expands Board of Directors with Appointment of Chris Peetz

ARQTArcutis Biotherapeutics2026-07-15 20:00 EST

Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

ARQTArcutis Biotherapeutics2026-07-08 12:00 EST

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Stock data

Close
25.08 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States